Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function

被引:70
作者
Ridderström, M
Masimirembwa, C
Trump-Kallmeyer, S
Ahlefelt, M
Otter, C
Anderson, TB [1 ]
机构
[1] AstraZeneca R&D, Dept Pharmacokinet & Drug Metab, Molndal, Sweden
[2] AstraZeneca R&D, Dept Biol Mol, Molndal, Sweden
[3] AstraZeneca R&D, AstraZeneca Struct Chem Lab, Molndal, Sweden
关键词
CYP2C9; cytochrome P450; active-site; mutagenesis; function; diclofenac;
D O I
10.1006/bbrc.2000.2538
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human cytochrome P450 2C9 (CYP2C9) is one of the major drug metabolising enzymes which exhibits a broad substrate specificity. The B-C loop is located in the active-site but has been difficult to model, owing to its diverse and flexible structure. To elucidate the function of the B-C loop we used homology modelling based on the Cyp102 structure in combination with functional studies of mutants using diclofenac as a model substrate for CYP2C9. The study shows the importance of the conserved arginine in position 97 and the arginine in position 108 for the catalytic function. The R97A mutant had a 13-fold higher K-m value while the V-max was in the same order as the wild type. The R108 mutant had a 100-fold lower activity with diclofenac compared to the wild-type enzyme. The other six mutants (S95A, F100A, L102A, E104A, R105A, and N107A) had kinetic parameters similar to the CYP2C9 wild-type. Our homology model based on the CYP102 structure as template indicates that R97, L102, and R105 are directed into the active site, whereas R108 is not. The change in catalytic function when arginine 97 was replaced with alanine and the orientation of this amino acid in our homology model indicates its importance for substrate interaction. (C) 2000 Academic Press.
引用
收藏
页码:983 / 987
页数:5
相关论文
共 26 条
[1]  
GOTOH O, 1992, J BIOL CHEM, V267, P83
[2]   Enzymatic determinants of the substrate specificity of CYP2C9:: Role of B′-C loop residues in providing the π-stacking anchor site for warfarin binding [J].
Haining, RL ;
Jones, JP ;
Henne, KR ;
Fisher, MB ;
Koop, DR ;
Trager, WF ;
Rettie, AE .
BIOCHEMISTRY, 1999, 38 (11) :3285-3292
[3]  
Halpert JR, 1998, DRUG METAB DISPOS, V26, P1223
[4]   STRUCTURE AND FUNCTION OF CYTOCHROMES-P450 - A COMPARATIVE-ANALYSIS OF 3 CRYSTAL-STRUCTURES [J].
HASEMANN, CA ;
KURUMBAIL, RG ;
BODDUPALLI, SS ;
PETERSON, JA ;
DEISENHOFER, J .
STRUCTURE, 1995, 3 (01) :41-62
[5]   CRYSTAL-STRUCTURE AND REFINEMENT OF CYTOCHROME P450(TERP) AT 2-CENTER-DOT-3 ANGSTROM RESOLUTION [J].
HASEMANN, CA ;
RAVICHANDRAN, KG ;
PETERSON, JA ;
DEISENHOFER, J .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 236 (04) :1169-1185
[6]   Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity [J].
Ibeanu, GC ;
Ghanayem, BI ;
Linko, P ;
Li, LP ;
Pedersen, LG ;
Goldstein, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) :12496-12501
[7]   Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19 [J].
Jung, F ;
Griffin, KJ ;
Song, W ;
Richardson, TH ;
Yang, M ;
Johnson, EF .
BIOCHEMISTRY, 1998, 37 (46) :16270-16279
[8]   DICTIONARY OF PROTEIN SECONDARY STRUCTURE - PATTERN-RECOGNITION OF HYDROGEN-BONDED AND GEOMETRICAL FEATURES [J].
KABSCH, W ;
SANDER, C .
BIOPOLYMERS, 1983, 22 (12) :2577-2637
[9]   Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily [J].
Lewis, DFV ;
Dickins, M ;
Weaver, RJ ;
Eddershaw, PJ ;
Goldfarb, PS ;
Tarbit, MH .
XENOBIOTICA, 1998, 28 (03) :235-268
[10]   The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid [J].
Li, HY ;
Poulos, TL .
NATURE STRUCTURAL BIOLOGY, 1997, 4 (02) :140-146